Tislelizumab Plus Chemotherapy Improves Progression-Free Survival in Nasopharyngeal Cancer

Caroline Helwick  /  August 25, 2022 - Supplement: Head & Neck Almanac

The addition of the checkpoint inhibitor tislelizumab to first-line chemotherapy significantly reduced the risk of disease progression or death by 50% and, despite a 49% crossover rate, numerically boosted overall survival in patients with recurrent or metastatic nasopharyngeal cancer, Zhang et al r...

DREAMseq Trial: In Advanced Melanoma With BRAF Mutations, Start With Immunotherapy

Caroline Helwick  /  December 10, 2021

 In the treatment of patients with advanced melanoma containing BRAF mutations, initial treatment with an immunotherapy combination achieved superior overall survival compared with targeted therapy in the phase III DREAMseq trial, also known as the ECOG-ACRIN EA6134 trial. The results were reported ...